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Abstract 
Atrial fibrillation (AF) is the most common atrial arrhythmia in adults worldwide.  
As medical advancements continue to contribute to an ever-increasing aging 
population, the burden of atrial fibrillation on the modern healthcare system 
continues to increase. Therapies are also evolving, for treatment of the 
arrhythmia itself, and stroke risk mitigation. Internists and cardiologists alike are, 
in most instances, the frontline contact for AF patients, and would benefit from 
remaining facile in their understanding of care options. In order to continue to 
deliver high-quality care to this expanding patient group, an updated, concise 
review for the clinician is prudent. This article provides a comprehensive 
summary of the current epidemiology and pathophysiology of AF, as well as 
contemporary procedural therapeutic options. 
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Epidemiology  
AF was discovered in the early 20th century and was initially believed to be a 
dysrhythmia of clinical insignificance.1,2 However, towards the end of the 20th and 
into the 21st century, AF has notably impacted morbidity and mortality, and has 
become a cog in the wheel of increasing health care utilization and cost.3,4 AF is 
the most common clinically significant arrhythmia, with a recent worldwide 
estimated prevalence of up to 33.5 million patients and affecting 2.5%-3.5% of 
populations across many countries, with developed countries’ incidence of AF 
twice that found in developing countries.5 This estimate from the recent Global 
Burden of Disease study did not include silent AF, which consequently can be 
associated with cryptogenic strokes, heart failure, and early mortality.6 5.2 million 
people are estimated to suffer from AF in the United States, a number that is 
expected to increase to 12.1 million over the next one to two decades.7 
 
AF significantly financially impacts public health.  In the United Kingdom, AF is 
estimated to account for 1% of the national budget, and AF costs $16-26 billion 
annually in medical expenditures in the United States.8,9,10 AF is associated with 
an estimated incremental medical cost of $8705 per patient per year, including 
inpatient, outpatient, and pharmacy costs.9 The majority of increased cost of AF 
is from hospitalization, stroke and heart failure care, and loss of economic 
productivity.8,11,12,13 Evaluation of the disability-adjusted life-years (DALYs) 
metric, a means of assessing the impact of disability of chronic disorders 
combining information on premature death (i.e., years of life lost) and disability 
caused by the chronic disorder (i.e., years lived with disability),11 indicated that 
from 1990 to 2010, the worldwide burden of DALY loss attributable to AF 
increased from 54 per 100,000 person-years to 65 per 100,000 person-years for 
men, and increased from 39 to 46 per 100,000 person-years for women.6  These 
increases reflect a growing global epidemic of AF that is both an economic and 
disability burden.   
 
With the increasing prevalence of AF and number of patients seeking care for 
AF, interest in understanding the arrhythmia and risk factors has increased. 
Several intrinsic traits have been linked to elevated risk of AF, particularly age, 
race, and gender. 
 
For every decade of life attained, the risk of developing AF doubles.14 The annual 
incidence of AF per 1000 persons in the Framingham population for those under 
65 is 1.9 in women and 3.1 in men, compared to 31.4 in women and 38 in men 
among those over 85 years of age.15 The lifetime risk of AF in the over-40 
Framingham population was estimated at 25%.16 The incidence of AF in a 
European population was found to be 1.1 per 1000 person-years in patients 55-
59 years of age, increasing to 20.7 per 1000 person-years in those over 80 years 
old.17  
 
Caucasians have a higher risk of incident AF than do African Americans, 
Hispanics, and Asians.18 There is a risk factor-AF paradox evident in the lower 
incidence of AF in African Americans despite a higher prevalence of AF risk 
factors.19,20 The Cardiovascular Health Study (CHS) first suggested this paradox, 
finding a 79% lower risk of AF in the African American study population.21 The 
CHS study was not the only population study to make this observation. The 
Analysis of the Atherosclerosis Risk in Communities (ARIC) study also observed 
that African Americans had a 41% lower adjusted risk of developing AF 
compared to Caucasians.19 A meta-analysis of 10 studies examining over 1 
million patients suggested that African Americans appeared to be protected from 
AF, demonstrating a 49% lower risk.22 To assess whether this was an 
environmental or genetic factor, Marcus et al. used genetic analysis to determine 
the degree of European ancestry in African Americans in the CHS and ARIC 
studies, and correlated this information with risk of developing incident AF.23 The 
study concluded that for every 10% increase in European ancestry there was a 
10% increased risk of incident AF, indicating that there likely is an undiscovered 
genetic predisposition to AF in those of European descent.  
 
Gender also impacts the incidence and effects of AF. Women tend to be more 
symptomatic from AF, with longer paroxysmal episodes and faster ventricular 
response rates during paroxysms.24 However, compared to men, women had a 
46% lower age-matched risk of AF in the ARIC study and a lower incidence of 
newly diagnosed AF in a Medicare database review (25 compared to 35 per 
1000 person-years).19,25 It is, however, well established that women have a 
higher risk of cardioembolic stroke from AF.26,27 In the Copenhagen City Heart 
Study, a population-based prospective cohort study, women had an independent 
2.5-fold increased risk of cardiovascular mortality related to AF.27 
 
Comorbidities and AF Risk Reduction 
The development of AF in any one patient involves many complex and 
incompletely understood mechanisms.  There are several important comorbid 
conditions that promote the development and maintenance of AF.  
Understanding these factors better is important and may translate into better 
treatment and prevention of AF.  The most well-described modifiable factors that 
increase risk of AF are congestive heart failure (CHF), hypertension, diabetes 
mellitus, obesity, alcohol consumption, and obstructive sleep apnea.28,29 Risk 
factor modification may impact the development and severity of AF, as illustrated 
in Figure 1.  
 
 
Congestive Heart Failure 
 
AF and CHF often share many comorbidities, and AF is associated with a 3-fold 
increase in the risk of incident heart failure.30,31 In the international Real-life 
global survey evaluating patients with Atrial Fibrillation (RealiseAF), the 
prevalence of CHF was associated with increasing persistence of AF (33% of 
those with paroxysmal AF had CHF, compared with 44% in persistent AF and 
56% in permanent AF).32 Also, the prevalence of AF is directly associated with 
New York Heart Association (NYHA) functional class: <10% in NYHA functional 
class I have AF, compared with up to 55% in NYHA functional class IV 
regardless of systolic function.33  
 
Patients with AF and CHF have a worse prognosis than with either component 
alone.  In the Framingham population, development of CHF in subjects with AF 
was associated with increased mortality in both men (HR 2.7; 95% CI 1.9-3.7) 
and women (HR 3.1; 95% CI 2.2-4.2).34 In the same population, subsequent 
occurrence of AF in those with CHF was associated with increased mortality in 
both men (HR 1.6; 95% CI 1.2-2.1) and women (HR 2.7; 95% CI 2.0-3.6).34 A 
meta-analysis evaluating CHF patients’ prognosis found an increase in mortality 
related to AF in 30,248 subjects from randomized trials (OR 1.4; 95% CI 1.32-
1.48; p<0.0001) and in 23,721 subjects from observational studies (OR 1.14; 
95% CI 1.03-1.26; p<0.05).35 
 
The physiologic interactions between AF and CHF that contribute to their co-
habitation are complex.  Experimental models indicate that AF is initiated and 
sustained when there is heterogeneity of repolarization throughout the atria, 
slowed atrial conduction, and a decreased atrial refractory period.36,37 Atrial 
tissue stretches in response to increased atrial pressure and volume, increasing 
triggered activity and changes in refractoriness, predisposing to AF.38 Atrial 
hypertrophy and chamber enlargement then leads to increased atrial automaticity 
and heterogeneity of depolarization.39 Neuro-hormonal milieu changes via renin-
angiotensin-aldosterone system (RAAS) activation in CHF promote extracellular 
matrix fibrosis, leading to heterogeneity of atrial repolarization and predisposing 
to the development of AF.36,37,40 Pulmonary vein cardiomyocyte activity may be 
angiotensin II sensitive, which may lead to AF initiation.41 Conversely, AF can 
lead to RAAS activation and may induce a tachycardia-mediated 
cardiomyopathy, again highlighting the complex interactions between AF and 
CHF.42,43,44   
 
Hypertension 
Hypertension is an independent risk factor for incident AF.  The Framingham 
cohort displayed an independent increased risk of AF by factors of 1.5 in men 
and 1.4 in women related to hypertension.14 Pre-hypertension range blood 
pressure has also been associated with increased risk of AF: data from the 
Women’s Health Study noted that the risk of incident AF during 12.4 years of 
follow-up was significantly increased in those with baseline systolic blood 
pressure 130 mmHg or diastolic blood pressure 90 mmHg.45 A study in middle-
aged men showed similar findings.46 Baseline systolic blood pressure 128 
mmHg or diastolic blood pressure 80 mmHg were associated with 1.5-fold and 
1.79-fold higher risk, respectively, of incident AF.  Hypertension increases 
sympathetic output which may lead to increased left atrial pressure and volume, 
as well as RAAS activation, thereby leading to atrial fibrosis, structural and 
electrical atrial remodeling, and promotion of AF.47   
 
It is therefore fitting to postulate that aggressive treatment of chronic 
hypertension could help to reduce the risk of AF.  Post-hoc analysis of the 
standard versus aggressive blood pressure lowering arms of the randomized 
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial indicate that 
targeting a systolic blood pressure of <120 mmHg compared with the “standard” 
target of <140 mmHg showed a statistically nonsignificant trend toward a lower 
incidence of AF.48   
 
Conceivably, “upstream” therapy with RAAS modulators, angiotensin converting 
enzyme inhibitors (ACEi), and angiotensin receptor blockers (ARB) may improve 
risk of AF, a notion mentioned in the 2014 major societal AF guidelines.49 Post-
hoc analysis of two large hypertension studies, the Losartan Intervention For End 
Point Reduction in Hypertension (LIFE)50 and Valsartan Antihypertensive Long-
Term Use (VALUE)51 trials, suggested that ACEi/ARB therapy may be of benefit 
in reducing incident AF.  The LIFE trial included hypertensive patients with left 
ventricular hypertrophy but without AF and showed therapy with losartan had 
similar efficacy in lowering blood pressure as atenolol, but was associated with a 
33% reduced risk of new-onset AF (p<0.001).50 In the VALUE trial, valsartan was 
associated with a lower incidence of AF compared with amlodipine (unadjusted 
HR 0.843, p=0.046).51 Conversely, a meta-analysis of 11 studies with 56,308 
patients evaluating the efficacy of ACEi or ARB therapy in preventing AF 
demonstrated no benefit in the hypertension subgroup.52 However, this meta-
analysis did not include the VALUE trial, only had 3 studies in the hypertension 
subgroup with only 2 evaluating new-onset AF, and there was significant 
interstudy heterogeneity.52 A Danish retrospective study of individuals with only 
hypertension showed that the use of ACEi or ARB as monotherapy was 
associated with a much lower risk of new-onset AF compared beta-blocker use 
(ACEi HR 0.12, 95% CI 0.10-0.15; and ARB HR 0.10, 95% CI 0.07-0.14) or 
diuretics (ACEi HR 0.51, 95% CI 0.44-0.59; and ARB HR 0.43, 95% CI 0.32-
0.58), but not compared with calcium channel blocker use.53 A recent meta-
analysis of 4 randomized clinical trials (RCTs) with 1050 patients showed 
telmisartan was more effective than other antihypertensive medications in 
reducing the burden of AF (HR 0.54, CI 0.34-0.86).54 Overall, these data suggest 
that there may be a role for RAAS modulation in preventing AF and reducing its 
recurrence, but certainly more studies are needed. 
 
Diabetes Mellitus 
20% of patients with AF have diabetes mellitus (DM).55 Hyperglycemia likely 
contributes to inflammation, oxidative stress, and formation of advanced 
glycosylation end-products (which can lead to hypertrophy and interstitial 
fibrosis). These factors can lead to electroanatomical remodeling of the left 
atrium and thereby promote AF.56  
 
DM is an independent contributor to new onset AF, as shown in the Framingham 
population in both men (OR 1.4) and women (OR 1.6).14 The VALUE trial also 
showed those with DM during follow-up to have a 50% increased risk of new-
onset AF.57 Furthermore, a meta-analysis including 1,686,097 patients indicated 
a 40% higher risk of AF in diabetics.58    
 
There are no convincing published data in support of “upstream” therapy to 
prevent AF in patients with DM.  However, a few reports suggest that the use of 
thiazolidinediones (TZDs) may contribute to AF risk reduction. TZDs are drugs 
that activate peroxisome proliferator-activated receptor-, reducing peripheral 
insulin resistance. The use of these agents is limited by their reported adverse 
effects including weight gain, CHF, and possibly bladder cancer.59 A Taiwan 
population-based cohort study evaluated 12,065 type 2 diabetic patients, and 
observed that the use of TZDs was associated with a 31% reduced adjusted risk 
of new onset AF.60 Gu et al. found in their 150 consecutive-patient cohort with 
type 2 DM undergoing pulmonary vein isolation (PVI) as part of a rhythm control 
strategy for AF that use of pioglitazone was associated with a higher rate of 
maintenance of sinus rhythm without antiarrhythmic therapy over nearly two 
years of follow-up (86 vs. 71%, p=0.034).61 The mechanism of this effect is 
unknown. However, as suggested by animal models, TZDs may attenuate 
electrical and structural atrial remodeling via their antioxidant and anti-
inflammatory properties.62 
 
Obesity 
Obesity, like AF, is a growing worldwide epidemic.63 Obesity is associated with 
increased left atrial dimensions,64 which may be mediated via lipoapoptosis65 and 
autonomic impairment.66 A 4% increase in the hazard of incident AF for each unit 
increase in BMI was noted in the Framingham population.67 Similar findings were 
noted in the Women’s Health Study,68 the ARIC study,69 and various other 
community cohort studies.70,71 The LEGACY study evaluated the effect and 
magnitude of weight loss on the burden of AF.72 They found a 6-fold increase in 
arrhythmia-free survival among those who achieved a stable weight loss of 
10%. 
 
Alcohol Consumption 
Alcohol consumption and AF are well linked.73,74 Alcohol intake can depress 
cardiac function, cause cardiac conduction abnormalities, and worsen interatrial 
electromechanical conduction delay.75,76 In addition, alcohol consumption has 
been noted to increase both vagal activity and possible triggers for paroxysmal 
AF, indicating a potential vagally mediated mechanism of AF initiation.77 In the 
Framingham population, those who consumed >3 drinks per day had a 34% 
increased risk of AF.78 A study of Swedish men and women found a 39% higher 
independent risk of AF in those who drank >14 drinks per week.79 A recent 
observation in Germany linked both acute alcohol intake (at Munich’s 
Octoberfest) and chronic alcohol use (in the general community) with autonomic 
changes that may predispose to arrhythmia.80 Limiting alcohol consumption could 
be important for preventing AF and reducing AF episodes. 
 
 
Sleep Apnea 
In otherwise healthy adults, obstructive sleep apnea (OSA) is found in 4% of 
women and 9% of men.81 Hypopnea and apnea during sleep, causing cycles of 
hypoxia and then recovery, is associated with increased sympathetic output and 
parasympathetic withdrawal, elevated blood pressure, and activation of 
inflammatory mediators, which may be associated with atrial arrhythmia 
initiation.82,83 In one study, 151 consecutive patients presenting for electrical 
cardioversion for AF were found to have more than twice the prevalence of OSA 
of 312 consecutive general cardiology patients without a history of AF.84  
 
It has been noted that treatment of OSA facilitates AF therapy. There is a higher 
AF recurrence rate in OSA patients after electrical cardioversion,85 a lower rate of 
response to anti-arrhythmic therapy,86 and an increased recurrence AF risk in 
patients undergoing PVI.87 Treatment continuous positive airway pressure 
(CPAP) has been shown to reduce AF recurrence after electrical cardioversion85 
and improves the success rate of pulmonary vein isolation in OSA patients.88–90 
 
Risk Factor Modification 
Targeting the numerous risk factors for AF could potentially reduce AF burden. 
This hypothesis was evaluated in a RCT of 150 overweight or obese patients 
who underwent aggressive risk factor management, either with or without 
concomitant intensive weight loss support.91 The treatment group showed 
significantly more weight loss (14.3 kg vs. 3.6 kg, p<0.001) and a decrease in AF 
frequency and symptomatic severity. The Aggressive Risk Factor Reduction 
Study for Atrial Fibrillation (ARREST-AF)92 was an observational study of patients 
with a BMI of at least 27 kg/m2 and at least one other cardiovascular risk factor 
(hypertension, impaired glucose tolerance or DM, hyperlipidemia, OSA, smoking, 
or excessive alcohol intake).  The intent was to evaluate the effect of weight loss 
and other risk factor modification on long-term outcomes after PVI.  ARREST-AF 
evaluated 61 patients who participated in a risk factor management program and 
88 patients who continued with routine standard care.  Following catheter 
ablation, all patients were evaluated every 3 to 6 months using a 7-day Holter 
monitor and a clinic visit. As seen in Figure 2, those in the risk factor 
management program had remarkably superior arrhythmia free survival following 
ablation (32.9% vs. 9.7%, P<0.001) and also after multiple ablations (87% vs. 
17.8%, P<0.001).  Risk factor modification was also associated with cardiac 
anatomical improvements such as reduction in left atrial volume, ventricular 
septal thickness, and left ventricular end diastolic diameter.  Larger RCTs are 
needed to establish the potential benefit of aggressive risk factor modification 
programs for patients undergoing AF ablation.  
 
AF Pathophysiology 
AF is characterized by the absence of distinct P waves on the electrocardiogram, 
disorderly atrial electrical activity, and most often irregular R-R intervals.49 The 
chaotic electrical activity of AF results in an absence of atrial contraction and 
induces further structural and electrical changes in the atria, which potentiate 
AF.37,93 While there is no consensus as of yet regarding the overall 
electrophysiological, genetic and anatomical basis for the genesis of AF, it seems 
unlikely that a single mechanism is to blame. Rather, AF is the end product of 
multiple pathogenic pathways.93,94 
A major breakthrough in our understanding and treatment AF was the 
identification of focal AF “triggers,” which usually are in the form of premature 
atrial depolarizations. The most common sources of these focal triggers are atrial 
myocytes making up muscle “sleeves” extending from the left atrium into the 
pulmonary veins (PV). Following transient ectopic tachycardias from PVs, the 
atrial electrical refractoriness is decreased, promoting AF initiation.95 Repeated 
firing and progressive atrial remodeling then enable AF to sustain itself via 
reentry within atrial tissue with heterogeneous conduction.96,97,98,99 
There are disparate views on how AF persists and maintains itself following the 
initiation of AF. The “multiple wavelet hypothesis” proposes that multiple 
independent reentrant wavelets exist, perpetuating the arrhythmia.100,101 Other 
competing theories include focal activity within the ganglionic plexi (collections of 
autonomic tissue within the atrium) or untethered macro-reentrant circuits in the 
form of smaller spiral reentrant drivers, often termed “rotors.”102,103 Likely one of 
these theories may predominate in a single patient, but all may contribute in 
some form and fashion in the maintenance in the storm that is AF. 
Early in the disease process, when AF is transient (or “paroxysmal”), triggered 
activity is likely the predominant mechanism. It is often observed that if AF is 
allowed to persist, it becomes more difficult to treat (i.e., that “AF begets AF”).37 
In the later stages of AF, due to ongoing electroanatomical atrial remodeling, the 
more complex mechanisms contribute to AF persistence. This thought process 
governs the treatment process of patients with AF.  In patients who have 
symptomatic paroxysmal AF, the focus of therapy is suppression of triggers, 
while the treatment of persistent AF includes substrate-based strategies.49,103 
As previously discussed, established risk factors can predispose patients to AF. 
The promotion of AF is likely linked to structural and electrical remodeling of the 
atria. Atrial histological remodeling can result from increased left atrial pressure 
and size, which leads to connective tissue disorganization and interstitial fibrosis, 
increasing the patient’s susceptibility to AF.104,105 These histologic alterations can 
slow atrial conduction velocity while increasing local heterogeneous conduction 
and conduction block.40,106,107,108,109 As discussed previously, RAAS activation 
can contribute as well to adverse remodeling through its proinflammatory and 
profibrotic characteristics,111,112,113 
As the atrial changes that promote AF continue, increased automaticity occurs as 
a result of altered calcium handling that occurs via calcium leak at the level of the 
sarcoplasmic reticulum, which may also affect conduction velocity and tissue 
refractoriness.114,115 Atrial myocytes’ compensatory response to the increased 
inward calcium current that results from frequent myocyte depolarization is to 
downregulate L-type calcium channels.  However, these changes also cause 
shortening of action potential duration, further reducing atrial refractoriness and 
further promoting AF, embodying the notion that “AF begets AF.”116 
AF also is linked to inflammation.117,118,119,120,121,122 Inflammatory markers, such as 
C-reactive protein (CRP) levels, are more elevated in patients with persistent AF 
than in those with paroxysmal AF.123 Higher CRP levels predict AF relapse after 
cardioversion and are associated with increased embolic risk.124 
Increased autonomic nervous system activity and age-associated structural 
fibrosis are also involved in AF initiation and maintenance.125,126 As analyzed on 
Holter monitor recordings, initiation of AF often occurs following an increase in 
adrenergic (sympathetic) input, followed by an abrupt parasympathetic 
predominance immediately prior to the initiation of AF.127 
The development of AF therefore results from myriad processes, including 
comorbidities that promote early atrial enlargement, atrial fibrosis causing 
conduction heterogeneity, inflammation, electrical remodeling, and autonomic 
remodeling. 
 
Rate Control vs. Rhythm Control  
The decision between the “rate control” or “rhythm control” strategies is a shared 
process between patients and their physicians. Atrioventricular nodal blockade 
(often with beta blockers, calcium channel blockers, and/or digitalis) is the basis 
for rate control, limiting the ventricular rate response to AF’s atrial electrical 
chaos. All patients with incident AF should be first treated with a ventricular rate 
control strategy, if needed, while the decision making process commences 
regarding the subacute treatment strategy goal, in order to help prevent a 
tachycardia-mediated cardiomyopathy. Sustained rapid ventricular response can 
induce significant CHF symptoms, even in the absence of overt left ventricular 
(LV) systolic dysfunction.44,49,128 
The recommended target heart rate for the rate control strategy has developed 
over time. The randomized prospective trial RACE II found in 614 patients with 
permanent AF over at least a 2 year time period that a lenient rate control 
strategy (resting HR <110 bpm) is at least as effective as strict rate control (<80 
bpm).129 Those with lenient rate control had far fewer total clinical visits 
compared to those in the strict rate control group (75 vs. 684, p<0.001). 
However, the primary composite endpoint of death from cardiovascular causes, 
hospitalization for heart failure, stroke, systolic embolism, bleeding, and life 
threatening arrhythmic events was similar in the two groups.  
After acute rate control is achieved, the decision is made whether to both restore 
and maintain sinus rhythm, termed “rhythm control,” or to continue with long-term 
rate control in the presence of continued atrial fibrillation. Rhythm control may 
utilize medical antiarrhythmic therapy, electrical cardioversion, and/or invasive 
catheter- or surgery-based procedures.49,130,131,132 Patient-specific factors 
including stage of AF (i.e., paroxysmal, persistent, or permanent), symptoms, 
age, comorbidities, and, importantly, patient preference should be considered.  
Although there are no trial data to support which initial treatment strategy is 
superior, expert consensus seems to support that a trial of restoration of sinus 
rhythm should be offered at the first presentation of AF.49,133 This approach offers 
early control of AF to patients with a potentially reversible cause of AF, or those 
with an isolated episode of AF. If AF does recur, patients will be in a better-
informed position to decide whether to continue simple rate control, or to pursue 
a rhythm control strategy if there was symptomatic improvement while in sinus 
rhythm. Particularly suitable patients for the rhythm control strategy include 
young people, those with “lone” atrial fibrillation, and those with substantial 
symptoms even with effective control of the ventricular rate.133 
Currently, the benefit of a rhythm control strategy with antiarrhythmic therapy, 
whether alone or in conjunction with electrical cardioversion and/or ablation, is 
recommended solely for symptom improvement and increase in quality of life.49 
No mortality benefit of pharmacological rhythm control has been established in 
randomized clinical trials, thus allowing limiting exposure to potential side effects 
of anti-arrhythmic drugs to those who are symptomatic. The Atrial Fibrillation 
Follow-up Investigation of Rhythm Management trial (AFFIRM) was the largest 
randomized trial comparing the rate- and rhythm-control strategies, and 
demonstrated similar all-cause mortality at five years (24 vs. 21%, p=0.08).134 
Some have argued that very symptomatic patients were likely underrepresented 
in AFFIRM, as those patients may not have been deemed appropriate for a rate 
control strategy. Others argue that the adverse drug effects and suboptimal 
efficacy of available antiarrhythmic therapy may have limited the benefit of 
rhythm control. In support of this argument, a post-hoc analysis of AFFIRM data 
demonstrated that rhythm restoration resulted in a gross mortality benefit, which 
was counteracted by an increase in mortality associated with antiarrhythmic 
use.135 Even among patients with HF, no differences between treatment 
strategies were found in overall survival, cardiovascular death, worsened heart 
failure, or stroke.136 In a separate study of patients randomized to a rate- or 
rhythm-control strategy for new-onset AF after cardiac surgery, there was no 
difference in death or other serious adverse events with a similar rate of freedom 
from AF on follow-up.137 To date there have been no randomized trials of an 
invasive (i.e., ablative) rhythm control strategy to assess its effect on mortality.  
 
Medical Antiarrhythmic Therapy 
Patients who are symptomatic from AF may have improved symptoms following 
the use of antiarrhythmic drugs (AADs) for maintenance of normal sinus rhythm. 
For those with AF-related cardiomyopathy, AADs may be used to reestablish 
normal rhythm and restore left ventricular function. AADs may also be helpful in 
facilitating electrical cardioversion after initially unsuccessful attempts. Generally, 
AADs are not used for patients with asymptomatic AF or in those with permanent 
AF who have elected to forego a rhythm control strategy. AADs’ use is often 
limited by contraindications to their use and by the emergence of adverse drug 
effects.138,139,140 
 
As depicted in Figure 3, several important factors determine the available AAD 
choices. These factors include the presence or absence of structural heart 
disease and/or heart failure, renal function, and left ventricular hypertrophy.138 
Use of flecainide and propafenone, which belong to the Class 1C AAD grouping 
in the Vaughan-Williams drug classification, is limited to patients with structurally 
normal hearts (i.e., normal left ventricular ejection fraction and LV wall thickness 
<1.5cm), and are contraindicated in patients with prior myocardial 
infarction.138,141,142,143,144,145,146 The Class III agents, sotalol and dofetilide, are 
contraindicated in those with creatinine clearance below 20 mL/min or QTc 
interval greater than 440 milliseconds.143,147–149 Initiation of dofetilide (or any dose 
increase) requires three days of inpatient monitoring of the QTc interval. Similar 
inpatient monitoring for sotalol is recommended as well, though not as 
strongly.148,149 Dronedarone, another Class III agent, is contraindicated in 
patients with advanced heart failure or a recent heart failure exacerbation, or in 
those who have had amiodarone-related lung toxicity.150–154 Amiodarone and 
dofetilide are the only antiarrhythmics available for use in the setting of LV 
systolic dysfunction.138,149,155–157 
 
Due to its high efficacy, ability to be used in patients with renal insufficiency and 
cardiomyopathy, and available intravenous formulation, amiodarone remains in 
frequent use, despite its typically not being a first line drug.155,158,159 The use of 
amiodarone is limited by its well-known potential toxicities including unfavorable 
effects in the lung, liver, thyroid, skin, and eyes, which requires monitoring (and 
potential drug discontinuation) during prolonged use.  
 
Long-term AAD efficacy for maintaining sinus rhythm ranges from 30-50%, with 
amiodarone being the most effective.138  
 
Stroke Prophylaxis and Bleeding Risk 
Risk Stratification  
The most feared complications of AF are stroke and systemic embolism, which 
carry significant morbidity and mortality.160,161 AF increases the risk of stroke 5-
fold.161 Valvular AF (i.e., AF related to mitral stenosis) may increase the risk of 
stroke 20-fold compared to a similar patient without valvular AF. 
 
A patient’s bleeding risk must be kept in mind when assessing stroke risk prior to 
administering anticoagulation. The most widely accepted tools for stroke risk 
stratification and bleeding risk stratification are the CHA2DS2-VASc and 
HASBLED scores, respectively (see Table 1).162,163 In addition to the original 
CHADS2 score, the CHA2DS2-VASc score includes as risk factors age ≥65 years, 
female sex, and vascular disease. The most recent AF guidelines advise oral 
anticoagulation in patients at high risk (i.e., CHA2DS2-VASc ≥2). While moderate 
risk patients (CHA2DS2-VASc=1) can consider no therapy, aspirin, or 
anticoagulation, expert opinion favors anticoagulation. The use of anticoagulation 
for moderate risk patients is the current recommendation from the European 
Society of Cardiology.164 For low risk patients (CHA2DS2-VASc=0), no 
antithrombotic therapy is recommended.49 A HASBLED score of 3 or greater 
predicts high bleeding risk, but no guidelines exist concerning withholding 
anticoagulation therapy based on bleeding risk. A higher bleeding risk score 
alone should not result in the decision to withhold oral anticoagulation. Rather, 
these scores help to identify patients with increased bleeding risk and can guide 
the clinician to aggressively treat factors that might lower the bleeding risk (e.g., 
blood pressure control). 
 
In addition to these epidemiological prediction scores, other temporal and 
anatomical factors are important when considering stroke risk in AF. The 
ASSERT trial reported a roughly 2-fold increase in stroke rate for patients with 
atrial high rate episodes lasting over 6 minutes as detected by and implanted 
cardiac device (pacemaker or defibrillator).165 Also, higher complexity of the left 
atrial appendage’s anatomy is associated with higher thrombotic stroke risk in 
AF.166 
 
Warfarin and antiplatelet agents were the focus of early trials examining stroke 
prevention in AF. Aspirin alone provides no significant stroke reduction, with the 
SPAF-1 trial alone suggesting any significant benefit.167,168 The antiplatelet drug 
clopidogrel was evaluated in conjunction with aspirin in the ACTIVE-A Trial, and 
showed no benefit in stroke risk reduction compared with aspirin alone, at a cost 
of increased bleeding events.169 The ACTIVE-W trial compared clopidogrel and 
aspirin to warfarin and found a 40% risk reduction for stroke and systemic 
embolism with warfarin use compared to dual-antiplatelet therapy.170 Although 
effective in reducing stroke rates, there are important limitations to the use of 
warfarin, such as the requirement for frequent INR monitoring, variable time in 
the therapeutic range (most often, INR 2-3), the required dietary constraints, and 
numerous drug-drug interactions.171  
 
Non-Warfarin Oral Anticoagulants  
Since 2010, four non-warfarin oral anticoagulants (also termed novel oral 
anticoagulants [NOACs] or, more recently, direct oral anticoagulants [DOACs]) 
have been approved for stroke and systemic embolism risk reduction in patients 
with non-valvular AF.172–175 The major trials leading to FDA approval of each 
agent are summarized in Table 2.   
 
The direct thrombin inhibitor, dabigatran (Pradaxa), was the first DOAC approved 
by the FDA. The 150 mg dose studied in the RE-LY trial demonstrated stroke risk 
reduction superiority compared to warfarin (HR 0.66, 95% CI 0.53-0.82), and was 
non-inferior for major bleeding (HR 0.93, 0.81-1.07).172 Soon thereafter, a factor 
Xa inhibitor, rivaroxaban (Xarelto), showed non-inferiority for reduction of stroke 
and systemic embolism (0.88, 0.75-1.03) as well as bleeding events (HR 1.04, 
0.90-1.20) as compared to warfarin therapy.173 Apixaban (Eliquis), another factor 
Xa inhibitor, is the only DOAC showing superiority over warfarin for both stroke 
risk reduction (HR 0.80, 0.67-0.95) and major bleeding (HR 0.69, 0.60-0.80).174 
Most recently, edoxaban (Savaysa) was compared to warfarin in The ENGAGE 
AF-TIMI 48 trial, and was non-inferior for reduction of strokes and systemic 
embolism (HR 0.88, 0.75-1.03) and superior regarding bleeding events (HR 0.80, 
0.71-0.91).175 All four DOACs significantly reduced intracranial hemorrhage 
compared with warfarin. 
 
There are many factors to consider when choosing a DOAC. They have variable 
dependence on renal clearance, with some requiring specific dose adjustments. 
Only apixaban has been approved for those with end-stage renal disease, 
although this recommendation is based on pharmacokinetic and not trial data. On 
the other hand, edoxaban should not be used in patients with high kidney 
performance (GFR >90 ml/min), due to excessively brisk drug clearance. The 
most recent published AHA/ACC focused update on management of patient’s 
with valvular heart disease (VHD) recommends warfarin therapy in the setting of 
AF and rheumatic mitral stenosis.176 However, either DOACs or warfarin may be 
used with other native VHD (e.g. mitral regurgitation or aortic and tricuspid valve 
disease).176 No specific recommendation is made for choice of anticoagulant in 
the setting of AF and a bioprosthetic heart valve, although the ARISTOTLE and 
ENGAGE AF-TIMI 48 trials included patients with prior valve repair or 
valvuloplasty, bioprosthetic valves, and native VHD, except for those who had 
moderate-severe mitral stenosis.174,175 The only available study evaluating DOAC 
use in patients with mechanical heart valves, RE-ALIGN, showed harm in the 
dabigatran group.177 To date, no trials have directly compared DOACs. 
 
Dabigatran is currently the only DOAC with a commercially available reversal 
agent. Idarucizumab (Praxbind) is a monoclonal antibody fragment that binds 
free and thrombin-bound dabigatran neutralizing its anticoagulant activity.178 
Other reversal agents under current investigation include andexanet, which 
reverses the anticoagulant effects of apixaban and rivaroxaban, and 
PER977/ciraparantag, a small molecule that reverses all DOACs and heparin 
agents.179–181 
 
The major DOAC trials included patients with a range of average CHADS2 
scores, ranging from 2.1±1.1 in the RE-LY and ARISTOTLE trials to 3.5±0.9 in 
ROCKET-AF. Therefore, caution must be maintained when drawing conclusions 
about using these drugs in patients with much higher or much lower risk. Overall, 
the DOACs show favorable efficacy and safety profiles when compared with 
warfarin. However, warfarin does remain an effective option for many patients, 
and it remains the only oral anticoagulant approved for use in the setting of 
prosthetic heart valves. 
 
 
Left Atrial Appendage Occlusion/Exclusion 
Due to its dead-end anatomy and trabeculated inner surface, the left atrial 
appendage (LAA) is the most common site of intracardiac thrombus 
formation.182,183 While OAC reduces thrombus formation risk, it does not 
completely eliminate stroke risk, and for some patients OAC is undesirable or 
frankly contraindicated. Because of these limitations, physical exclusion of the 
LAA in addition to, or as a replacement for, OAC has gained increased 
considerable interest. 
  
Surgical LAA excision is frequently performed along with other cardiac surgery, 
whether the “main” procedure is solely targeted at AF treatment or is concomitant 
with other therapy (e.g., valve repair/replacement).184 Standalone LAA excision 
also has been studied, and has been shown to be safe and effective.185 Newer 
technologies, such as the AtriClip external closure device, make surgical LAA 
closure technically easier and more effective.186 To avoid the inherent 
disadvantage of invasiveness of a surgical procedure, percutaneous therapies for 
LAA exclusion or occlusion have gained favor.187 The most promising 
technologies are the intracardiac Watchman LAA occluder (Boston Scientific, 
Marlborough, MA) and the LARIAT system (SentreHEART Inc., Redwood City, 
CA), which closes the LAA orifice with a suture delivered via a subxiphoid 
epicardial approach. These devices are depicted in Figure 4. 
 
The PROTECT-AF trial evaluated the efficacy of stroke risk reduction of the 
Watchman device compared with OAC in warfarin-eligible AF patients, and at 
first found LAA occlusion to be noninferior to OAC for stroke reduction (RR 0.71, 
95% CI 0.44-1.3).188,189 There were initial concerns about procedure-related 
adverse events. However, with experience these events became less frequent, 
likely related to a significant learning curve.190 During continued follow-up, the 
Watchman device was shown to be better than warfarin for stroke risk reduction 
(HR 0.61, 95% CI 0.38-0.97) and similar regarding safety.191 The PREVAIL trial 
and EWOLUTION registry subsequently confirmed Watchman’s high implant 
success rate and acceptably low risk.192,193 Currently, the Watchman device is 
FDA-approved for stroke prophylaxis in patients who are warfarin-eligible but for 
whom long-term OAC is unattractive.  
 
The Watchman device has been shown to be superior to historical controls in 
patients ineligible for warfarin.194,195 However, no randomized study has been 
performed evaluating Watchman and an inactive control.  
 
The LARIAT suture/snare system is FDA-approved for soft tissue closure. It has 
been used off-label to close the LAA using an epicardial approach. LARIAT’s 
potential advantage over Watchman is that it does not leave a device within the 
heart, potentially lessening the need for even short-term OAC. However, its 
weakness may be the higher rate of significant procedural complications and the 
incidence of incomplete LAA closure.196 A 309-patient meta-analysis found a 
procedural success rate of 90%, with a 2.6% rate of severe complications.197 
Similar to the Watchman experience, the rates of successful implantation and 
adverse events have shown a substantial learning curve trend.198 A recent 
registry of 682 patients found complete LAA closure in 98%, with a severe 
adverse event rate of only 1.6%.199 However, at follow-up, incomplete LAA 
closure was detected in 7% of examined patients.199 
 
Currently, only warfarin has been used as the active control in comparison to 
LAA exclusion. Whether LAA closure maintains similar non-inferiority to DOACs, 
which appear to be safer than warfarin, remains to be seen.  
 
 
Atrial Fibrillation Ablation 
Catheter ablation of AF has evolved considerably to become safer and more 
successful over the past 10 years, and is now one of the most common cardiac 
procedures in the United States.200  
 
The electrophysiological principles essential to AF include an inducing trigger 
paired with an underlying substrate which is required to sustain the 
arrhythmia.200,201 As previously noted, the PVs are the most frequent areas 
where atrial ectopy triggering AF arise.202,203 Myocardial “sleeves” extending from 
the PVs are the primary origin of these triggers in >80% of patients with 
paroxysmal AF.204,205,206 Because of this common site of initiation, complete 
electrical isolation of the pulmonary veins (PVI) is usually the primary endpoint in 
catheter ablation of AF.49,204,205,207  
 
During a PVI procedure, lesions are created encircling the antrum the pulmonary 
veins, which results in non-conducting scar, thereby electrically isolating the PV 
muscle sleeves and their triggers from the rest of the myocardium.208 This is 
commonly performed either with delivery of radiofrequency energy via an 
ablation catheter delivering connecting circumferential lesions around the veins, 
or via cryo-injury with a cryoablation balloon-tipped catheter. The recent increase 
in ablation-based therapy as part of the rhythm control strategy has been driven 
by clinical trials noting the superiority of catheter-based PVI over antiarrhythmic 
medical therapy in longterm maintenance of sinus rhythm.209,210,211,212 Especially 
in patients with persistent AF, PVI often is supplemented with other ablation, 
including isolation of other veins (e.g., the SVC), cavotricuspid isthmus ablation, 
and/or elimination of other non-PV triggers. 
 
Selecting the appropriate patient for catheter based AF therapy is critical for 
maximizing success and minimizing procedural risk. Specific patient factors to 
consider include the severity and frequency of symptoms, tolerability of medical 
therapy, age, and underlying comorbidities.200 The physician and patient both 
should understand the goals of care and procedural risks, and should have 
realistic expectations of procedural outcomes.  While success rates of catheter 
ablation for AF have varied in clinical trials, the procedure can be very effective in 
individual patients.  
 
Initial trials evaluated paroxysmal AF patients with minimal structural heart 
disease who had failed therapy with at least one antiarrhythmic drug. 12-month 
success rates ranged from 66% to 86%.209,210,211,212 Clearly, AF ablation is more 
successful in patients with paroxysmal AF, which likely is related to the presence 
of less underlying abnormal substrate than in persistent AF patients.213,214 
However, many patients with paroxysmal AF will require repeat ablation 
procedures before there is durable success.215,216  
In paroxysmal AF patients who have failed or are intolerant to anti-arrhythmic 
therapy, PVI currently has a Class I recommendation from the Heart Rhythm 
Society and the American College of Cardiology/American Heart Association 
Task Force on Practice Guidelines for the Use of Catheter Ablation to Maintain 
Sinus Rhythm.217 Table 3 summarizes the most recent guidelines for AF ablation. 
Despite the generally high levels of recommendation supporting ablation, it 
cannot be emphasized enough that the decision to proceed with PVI should be 
made on an individualized basis. The lower success rates of ablation in those 
with more advanced AF and significant structural heart disease, and the frequent 
need for repeat procedures, resulted in Class IIa and IIb recommendations for 
ablation in patients with persistent AF and long standing (>12 months) persistent 
AF, respectively.217 For example, recent success rates of maintaining sinus 
rhythm without antiarrhythmic therapy after PVI for paroxysmal AF are over 80% 
at one year. However, in patients with persistent AF, 40-50% of patients require a 
repeat procedure, after which the rate of long-term success can reach 70%.218,219  
Table 4 summarizes several RCTs examining efficacy of maintenance of sinus 
rhythm after PVI. 
Currently, in general AF ablation should only be offered to appropriate patients 
with symptomatic AF, and only for the indication of enhancing quality of life.200 
Though AF is associated with an increased risk of stroke, heart failure, and 
death, it is currently unclear whether PVI reduces the long-term risk of these 
consequences,34,220 Currently, multicenter RCTs are being conducted to assess 
whether PVI-based intervention early in the AF course can reduce mortality and 
stroke risk when compared to treatment with rate- and rhythm-control medication 
alone.221,222  
 
In contrast to the conventional dogma that atrial fibrillation is disorganized 
electrical chaos, more recent evidence implicates arrhythmic maintenance due to 
sites of organized reentry, termed rotors.201,223 There has been recent interest in 
identifying rotors in real time, allowing them to be ablation targets, in addition to 
conventional PVI, in order to potentially increase the therapeutic efficacy of an 
ablation strategy. This ablation strategy attempts to anatomically localize rotors 
using 3-d imaging guidance and a multipole “basket” catheter in the atria, and is 
termed Focal Impulse and Rotor Modulation (FIRM) ablation.224 Early trials 
indicated that FIRM ablation plus PVI improved the procedural success rate of 
compared with standalone PVI.224,225 Subsequently, however, the OASIS trial, a 
randomized trial in patients with persistent AF, indicated that FIRM ablation 
combined with PVI was associated with a higher rate of AF recurrence at follow-
up (mean of 12  7 months) compared with more traditional approach, which in 
this study included PVI with left atrial posterior wall and non-pulmonary vein 
trigger ablation.226 However the publishing editor retracted the publication, due to 
concerns about the randomization process and early enrollment of patients. 
Nevertheless, ongoing randomized trials assessing the short- and long-term 
efficacy of FIRM ablation in combination with PVI are eagerly anticipated.   
 
Surgical and Hybrid Approaches to AF Treatment 
For AF patients undergoing open chest cardiac surgery for other indications (e.g., 
valve repair/replacement or coronary bypass surgery), surgical AF treatment 
should be considered. Surgical AF therapy employs strategic creation of scar 
lines in order to “debulk” the atrial substrate and prevent AF wavelet 
propagation.223 The initial technique, termed the Cox Maze procedure, was 
developed in the 1980s and involved directly cutting the atria and sewing them 
back together, in order to form electrically inert scar lines.227 Currently, more 
often surgical radiofrequency energy and/or cryoablation techniques are 
employed to create scar.227 Due to the invasive nature of the procedure and and 
its accompanying morbidity, today stand-alone open surgical PVI is infrequently 
recommended.217  
 
A more recent team-based ablation strategy, combining both a minimally invasive 
surgical approach with a subsequent percutaneous endocardial ablation, has 
evolved, often termed the “hybrid” or “convergent” procedure.228 This strategy is 
thought to offer the “best of both worlds,” combining the high efficacy of 
transmural linear ablation lesions via surgical visualization with the percutaneous 
catheter-based procedure (performed immediately following surgery or later in a 
“staged” fashion) of an electrophysiologist, who can confirm PV isolation and/or 
deliver supplementary endocardial lesions if needed. Reports of individual 
centers’ experience indicate very high success rates in freedom from AF during 
long-term follow-up in both paroxysmal and persistent AF.229,230  
 
 Conclusion 
Atrial fibrillation continues to expand its status as a global epidemic, with 
increasing prevalence and clinical importance. To date there remains no definite 
cure, and our ability to treat symptomatic patients remains suboptimal. Due to the 
growing recognition of its untoward impact on morbidity and mortality, there is 
more incentive for physicians and scientists to more closely investigate the 
underlying mechanisms of AF.  Over time, an improved understanding of the 
epidemiology and underlying pathophysiology of AF will result in further 
advances in the prevention and therapy of AF. 
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Figure 1. Risk factor modification in atrial fibrillation and its intended effects. 
Reproduced with permission from Morin et al. Mayo Clin Proc. 2016;91:1778-
1810. 
 
AF=atrial fibrillation. ACEi=angiotensin converting enzyme inhibitor. 
ARB=angiotensin receptor blocker. DM=diabetes mellitus.  
CHF=congestive heart failure. CPAP=continuous positive airway pressure. 
EtOH=ethyl alcohol consumption. HTN=hypertension. LA=left atrium. 
OSA=obstructive sleep apnea. OMT=optimal medical therapy.  
SBP=systolic blood pressure. TZD=thiazolidinedione.  
RAAS=renin-angiotensin-aldosterone system.  
 
  
Figure 2. Atrial fibrillation-free survival in the ARREST-AF trial. Reproduced with 
permission from Pathak et al. J Am Coll Cardiol 2014;64:2222-2231. 
 
AF=atrial fibrillation. RFM=risk factor management. 
 
 
 
 
 
  
 
Figure 3. Proposed rhythm control drug therapy of atrial fibrillation. Absent 
structural heart disease, any antiarrhythmic drug with the exception of 
amiodarone is first line.  In patients with CAD dronedarone, dofetilide and sotalol 
are first-line agents. For patients with CHF amiodarone and dofetilide are first-
line therapy. Only dronedarone and amiodarone are recommended for patients 
with left ventricular hypertrophy with wall thickness >1.5cm. Catheter ablation 
prior to antiarrhythmic drug therapy is a IIa and IIb indication for patients with 
paroxysmal and persistent atrial fibrillation, respectively. Reproduced with 
permission from Morin et al. Mayo Clin Proc. 2016;91:1778-1810. 
 
CAD=coronary artery disease. CHF=congestive heart failure. 
 
 
 
 
 
  
Figure 4. Panel A LARIAT system, note the intracardiac (catheter/balloon/magnet) 
portion interacting with the epicardially-delivered magnetic guidewire and 
preloaded catheter-delivered suture, a fluoroscopic image just prior to LARIAT 
suture deployment is provided. Panel B Watchman device, consisting of a metallic 
frame with fixation barbs and a polyester fabric covering the atrial face of the 
device, fluoroscopic image of a Watchman being deployed is provided. Reproduced 
with permission from Lin et al. Prog Cardiovasc Dis 2015;58(2):195-201 and 
Fountain et al. Am Heart J 2006;151:956- 61. 
 
A. 
  
 
B.  
   
 Table 1. CHA2DS2-VASc and HAS-BLED components, scoring methods, and risk 
calculators. Reproduced with permission from Morin et al. Mayo Clin Proc. 
2016;91:1778-1810. 
 
CHF=congestive heart failure. DM=diabetes mellitus. HTN=hypertension. 
INR=international normalized ratio. TIA=transient ischemic attack. 
 
 
 
 
  
Table 2. A comparison of DOAC approval trials. Average CHADS2 score, and 
hazard ratios with confidence intervals for stroke and systemic embolism, major 
bleeding, and intracranial hemorrhage are included. Dose adjustment indications 
are also listed. Reproduced with permission from Morin et al. Mayo Clin Proc. 
2016;91:1778-1810. 
 
*indicates that the drug met non-inferiority criteria for the endpoint, compared to 
warfarin. **indicates that the drug met superiority criteria for the endpoint, 
compared to warfarin.  
 
bid=twice daily. CHADS2=congestive heart failure; hypertension; age >75 years; 
diabetes mellitus; stroke, transient ischemic attack, or systemic embolism. 
GFR=glomerular filtration rate. qd=daily.  
 
 Dabigatran  
150 mg bid 
RE-LY 
n=18,113 
Rivaroxaban  
20 mg qd 
ROCKET AF 
n=14,264 
Apixaban  
5 mg bid 
ARISTOTLE 
n=18,201 
Edoxaban  
60 mg qd 
ENGAGE AF/TIMI-48 
n=21,105 
CHADS2 2.1 3.5 2.1 2.8 
Stroke and 
systemic 
embolism 
0.66 (0.53-0.82) ** 0.88 (0.75-1.03) * 0.80 (0.67-0.95) ** 0.88 (0.75-1.03) * 
Major bleeding 0.93 (0.81-1.07) * 1.04 (0.90-1.20) * 0.69 (0.6-0.8) ** 0.80 (0.71-0.91) ** 
Intracranial 
hemorrhage 
0.40 (0.27-0.60) ** 0.67 (0.47-0.93) ** 0.42 (0.30-0.38) ** 0.47 (0.34-0.67) ** 
Dose 
adjustment 
75 mg bid if 
GFR 15-30 ml/min 
15 mg qd if 
GFR 15-50 ml/min 
2.5 mg bid for ≥2 of: 
Cr >1.5, Age >80y, 
weight <60 kg 
30 mg qd if 
GFR 15-50 ml/min 
 
  
Table 3. AHA/ACC/HRS Practice guideline for the management of patients with 
atrial fibrillation: Recommendations for catheter ablation to maintain sinus 
rhythm. Reproduced with permission from January, C.T., et al., 2014 
AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a 
report of the American College of Cardiology/American Heart Association Task 
Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol, 
2014. 64(21):e1-76. 
 
Class I (Benefit >>> Risk; Procedure/treatment SHOULD be performed) 
1. AF catheter ablation is useful for symptomatic paroxysmal AF refractory or 
intolerant to at least 1 class I or III antiarrhythmic medication when a 
rhythm-control strategy is desired. (Level of Evidence: A) 
2. Before consideration of AF catheter ablation, assessment of the procedural 
risks and outcomes relevant to the individual patient is recommended. (Level 
of Evidence: C) 
 
Class IIa (Benefit >> Risk; IT IS REASONABLE to perform 
procedure/treatment) 
1. AF catheter ablation is reasonable for some patients with symptomatic 
persistent AF refractory or intolerant to at least 1 class I or III antiarrhythmic 
medication. (Level of Evidence: A) 
2. In patients with recurrent symptomatic paroxysmal AF, catheter ablation is a 
reasonable initial rhythm control strategy before therapeutic trials of 
antiarrhythmic drug therapy, after weighing the risks and outcomes of drug 
and ablation therapy. (Level of Evidence: B) 
 
Class IIb (Benefit  Risk; Procedure/treatment MAY BE CONSIDERED) 
1. AF catheter ablation may be considered for symptomatic long-standing (>12 
months) persistent AF refractory or intolerant to at least 1 class I or III 
antiarrhythmic medication when a rhythm-control strategy is desired. (Level 
of Evidence: B) 
2. AF catheter ablation may be considered before initiation of antiarrhythmic 
drug therapy with a class I or III antiarrhythmic medication for symptomatic 
persistent AF when a rhythm-control strategy is desired. (Level of Evidence: 
C) 
 
Class III (No benefit, or potential HARM; Procedure/treatment IS 
CONTRAINDICATED) 
1. AF catheter ablation should not be performed in patients who cannot be 
treated with anticoagulant therapy during and after the procedure. (Level of 
Evidence: C) 
2. AF catheter ablation to restore sinus rhythm should not be performed with 
the sole intent of obviating the need for anticoagulation. (Level of Evidence: C) 
 
Table 4. Catheter ablation versus antiarrhythmic drug therapy for management of 
atrial fibrillation trials. “Second line therapy” indicates atrial fibrillation recurrence 
despite previous management with at least one antiarrhythmic drug.  
Reproduced with permission from Morin et al. Mayo Clin Proc. 2016;91:1778-
1810. 
 
CA, catheter ablation; AAD, anti-arrhythmic drugs; AF, atrial fibrillation; yr, year; 
mo, month; A4 Catheter Ablation versus Antiarrhythmic Drugs for Atrial 
Fibrillation; APAF, Ablate and Pace in Atrial Fibrillation; CACAF, Catheter 
Ablation for the Cure of Atrial Fibrillation; RAAFT, Radiofrequency Ablation for 
Atrial Fibrillation Trial; STOP-AF, Sustained Treatment of Paroxysmal Atrial 
Fibrillation; SARA, Study of Ablation versus antiaRrhythmic drugs in persistent 
Atrial fibrillation. 
 
             
Study 
Design 
Size  
(n) 
Paroxysmal 
(%) 
                       Freedom 
from AF recurrence 
(%)     
   Follow-up        CA          
AAD                 P   
Krittayaphong, 
2003 
 
CA as 
second line 
therapy* 
compared to 
amiodarone 
30  70%       1 yr                 79%          
40%              0.018 
Wazni, 2005 
RAAFT 
 
CA as first 
line therapy 
70 96%       1 yr                 87%          
37%            <0.001 
Stabile, 2005 
CACAF 
 
CA as 
second line 
therapy  
137 67%        1 yr              55.9%         
8.7%          <0.001                 
Pappone, 
2006 
APAF 
 
CA as 
second line 
therapy in 
paroxysmal 
AF 
198 100%        1 yr                 93%           
35%         <0.001 
Oral, 2006 
 
CA as 
second line 
therapy in  
chronic AF 
146 0%        1 yr                  74%           
58%            0.05 
Jais, 2008 
A4 
 
CA as 
second line 
therapy in 
paroxysmal 
AF 
112 100%        1 yr                  89%          
23%       <0.0001 
Forleo, 2009 CA as 
second line 
70 41%        1 yr                  80%         
42.9%         0.001 
 therapy in 
paroxysmal 
AF patients 
with type 2 
diabetes 
Wilber, 2010 
Thermocool 
 
CA as 
second line 
therapy in 
paroxysmal 
AF 
167 100%      9 mo                  66%         
16%          <0.001 
(after a 3-mo             
blanking period) 
Packer, 2013 
STOP-AF 
 
Cryoballoon 
ablation as 
second line 
therapy in 
paroxysmal 
AF 
245 78%      1 yr                   69.9%        
7.3%        <0.001   
 
Cosedis 
Neilsen, 2012 
MANTRA-
PAF 
 
CA as first 
line therapy 
in 
paroxysmal 
AF 
294 100%      2 yr                     85%         
71%          0.004 
Morillo, 2014 
RAAFT2 
 
CA as first 
line therapy 
in 
paroxysmal 
AF 
127 98%      2 yr                     53%          
41%          0.03 
Mont, 2014 
SARA 
CA as 
second line 
therapy in 
persistent 
AF 
146 0%      1 yr                   70.4%       
43.7%        0.002 
 
 
